Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Apr 27;82(10):1682–1688. doi: 10.1054/bjoc.2000.1118

Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR

H Das 1, T Koizumi 1, T Sugimoto 1, S Chakraborty 1, T Ichimura 2, K Hasegawa 2, R Nishimura 1,2
PMCID: PMC2374514  PMID: 10817504

Abstract

Alterations in the expression of Fas (CD95/APO-1) and its ligand (FasL) have been demonstrated in various types of cancers as a mechanism for tumour cell to escape from the immune system. In the present study, we evaluated the expression of the Fas and FasL genes in a wide range of primary gynaecological carcinomas. These included 31 ovarian, 29 cervical and 25 endometrial carcinoma tissues as well as four ovarian and three cervical carcinoma cell lines. Our real-time quantitative reverse transcription polymerase chain reaction analysis revealed that down-regulation of Fas expression is more prominent than the up-regulation of FasL expression in all types of gynaecological cancer studied. This down-regulation of Fas expression was also true for the seven carcinoma cell lines. Only one cervical carcinoma cell line, DoT, exhibited a high level of FasL expression. These results indicated that down-regulation of Fas expression is a common abnormality in many types of cancers including gynaecological cancers, whereas an increase in FasL expression is not a common phenomenon in these cancers. © 2000 Cancer Research Campaign

Keywords: Fas, FasL, quantitative PCR, primary tumours

Full Text

The Full Text of this article is available as a PDF (116.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson M. R., Tough T. W., Davis-Smith T., Braddy S., Falk B., Schooley K. A., Goodwin R. G., Smith C. A., Ramsdell F., Lynch D. H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995 Jan 1;181(1):71–77. doi: 10.1084/jem.181.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R. C. A role for CD95 ligand in preventing graft rejection. Nature. 1995 Oct 19;377(6550):630–632. doi: 10.1038/377630a0. [DOI] [PubMed] [Google Scholar]
  3. Daniel P. T., Krammer P. H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol. 1994 Jun 15;152(12):5624–5632. [PubMed] [Google Scholar]
  4. Debatin K. M., Krammer P. H. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukemia. 1995 May;9(5):815–820. [PubMed] [Google Scholar]
  5. Evan G., Littlewood T. A matter of life and cell death. Science. 1998 Aug 28;281(5381):1317–1322. doi: 10.1126/science.281.5381.1317. [DOI] [PubMed] [Google Scholar]
  6. Fenton R. G., Hixon J. A., Wright P. W., Brooks A. D., Sayers T. J. Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Res. 1998 Aug 1;58(15):3391–3400. [PubMed] [Google Scholar]
  7. Gibson U. E., Heid C. A., Williams P. M. A novel method for real time quantitative RT-PCR. Genome Res. 1996 Oct;6(10):995–1001. doi: 10.1101/gr.6.10.995. [DOI] [PubMed] [Google Scholar]
  8. Gratas C., Tohma Y., Barnas C., Taniere P., Hainaut P., Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998 May 15;58(10):2057–2062. [PubMed] [Google Scholar]
  9. Griffith T. S., Brunner T., Fletcher S. M., Green D. R., Ferguson T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995 Nov 17;270(5239):1189–1192. doi: 10.1126/science.270.5239.1189. [DOI] [PubMed] [Google Scholar]
  10. Guo M. W., Mori E., Xu J. P., Mori T. Identification of Fas antigen associated with apoptotic cell death in murine ovary. Biochem Biophys Res Commun. 1994 Sep 30;203(3):1438–1446. doi: 10.1006/bbrc.1994.2346. [DOI] [PubMed] [Google Scholar]
  11. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996 Nov 22;274(5291):1363–1366. doi: 10.1126/science.274.5291.1363. [DOI] [PubMed] [Google Scholar]
  12. Hueber A. O., Zörnig M., Lyon D., Suda T., Nagata S., Evan G. I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 1997 Nov 14;278(5341):1305–1309. doi: 10.1126/science.278.5341.1305. [DOI] [PubMed] [Google Scholar]
  13. Imai A., Horibe S., Takagi A., Ohno T., Tamaya T. Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors. Eur J Obstet Gynecol Reprod Biol. 1997 Jul;74(1):73–78. doi: 10.1016/s0301-2115(97)02750-4. [DOI] [PubMed] [Google Scholar]
  14. Ju S. T., Cui H., Panka D. J., Ettinger R., Marshak-Rothstein A. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4185–4189. doi: 10.1073/pnas.91.10.4185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Keane M. M., Ettenberg S. A., Lowrey G. A., Russell E. K., Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 1996 Oct 15;56(20):4791–4798. [PubMed] [Google Scholar]
  16. Kellogg D. E., Sninsky J. J., Kwok S. Quantitation of HIV-1 proviral DNA relative to cellular DNA by the polymerase chain reaction. Anal Biochem. 1990 Sep;189(2):202–208. doi: 10.1016/0003-2697(90)90108-l. [DOI] [PubMed] [Google Scholar]
  17. Leithäuser F., Dhein J., Mechtersheimer G., Koretz K., Brüderlein S., Henne C., Schmidt A., Debatin K. M., Krammer P. H., Möller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993 Oct;69(4):415–429. [PubMed] [Google Scholar]
  18. Mensink E., van de Locht A., Schattenberg A., Linders E., Schaap N., Geurts van Kessel A., De Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998 Aug;102(3):768–774. doi: 10.1046/j.1365-2141.1998.00823.x. [DOI] [PubMed] [Google Scholar]
  19. Micheau O., Solary E., Hammann A., Martin F., Dimanche-Boitrel M. T. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst. 1997 Jun 4;89(11):783–789. doi: 10.1093/jnci/89.11.783. [DOI] [PubMed] [Google Scholar]
  20. Möller P., Koretz K., Leithäuser F., Brüderlein S., Henne C., Quentmeier A., Krammer P. H. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 1994 May 1;57(3):371–377. doi: 10.1002/ijc.2910570314. [DOI] [PubMed] [Google Scholar]
  21. Müller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S. L., Galle P. R., Stremmel W., Oren M. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998 Dec 7;188(11):2033–2045. doi: 10.1084/jem.188.11.2033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nagata S., Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449–1456. doi: 10.1126/science.7533326. [DOI] [PubMed] [Google Scholar]
  23. Niehans G. A., Brunner T., Frizelle S. P., Liston J. C., Salerno C. T., Knapp D. J., Green D. R., Kratzke R. A. Human lung carcinomas express Fas ligand. Cancer Res. 1997 Mar 15;57(6):1007–1012. [PubMed] [Google Scholar]
  24. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996 Sep 1;184(3):1075–1082. doi: 10.1084/jem.184.3.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Owen-Schaub L. B., Radinsky R., Kruzel E., Berry K., Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994 Mar 15;54(6):1580–1586. [PubMed] [Google Scholar]
  26. Rissoan M. C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., Liu Y. J. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999 Feb 19;283(5405):1183–1186. doi: 10.1126/science.283.5405.1183. [DOI] [PubMed] [Google Scholar]
  27. Sheard M. A., Vojtesek B., Janakova L., Kovarik J., Zaloudik J. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer. 1997 Nov 27;73(5):757–762. doi: 10.1002/(sici)1097-0215(19971127)73:5<757::aid-ijc24>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  28. Shima Y., Nishimoto N., Ogata A., Fujii Y., Yoshizaki K., Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 1995 Feb 1;85(3):757–764. [PubMed] [Google Scholar]
  29. Shiraki K., Tsuji N., Shioda T., Isselbacher K. J., Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6420–6425. doi: 10.1073/pnas.94.12.6420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med. 1996 Dec;2(12):1361–1366. doi: 10.1038/nm1296-1361. [DOI] [PubMed] [Google Scholar]
  31. Suzuki A., Enari M., Eguchi Y., Matsuzawa A., Nagata S., Tsujimoto Y., Iguchi T. Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J. 1996 Jan 15;15(2):211–215. [PMC free article] [PubMed] [Google Scholar]
  32. Tabibzadeh S., Zupi E., Babaknia A., Liu R., Marconi D., Romanini C. Site and menstrual cycle-dependent expression of proteins of the tumour necrosis factor (TNF) receptor family, and BCL-2 oncoprotein and phase-specific production of TNF alpha in human endometrium. Hum Reprod. 1995 Feb;10(2):277–286. doi: 10.1093/oxfordjournals.humrep.a135928. [DOI] [PubMed] [Google Scholar]
  33. Takagi A., Imai A., Horibe S., Ohno T., Tamaya T. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep. 1998 Mar-Apr;5(2):377–380. doi: 10.3892/or.5.2.377. [DOI] [PubMed] [Google Scholar]
  34. Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science. 1995 Mar 10;267(5203):1456–1462. doi: 10.1126/science.7878464. [DOI] [PubMed] [Google Scholar]
  35. Xerri L., Devilard E., Hassoun J., Mawas C., Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol. 1997 Apr;50(2):87–91. doi: 10.1136/mp.50.2.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yonehara S., Nishimura Y., Kishil S., Yonehara M., Takazawa K., Tamatani T., Ishii A. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int Immunol. 1994 Dec;6(12):1849–1856. doi: 10.1093/intimm/6.12.1849. [DOI] [PubMed] [Google Scholar]
  37. Zörnig M., Grzeschiczek A., Kowalski M. B., Hartmann K. U., Möröy T. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene. 1995 Jun 15;10(12):2397–2401. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES